Russell Beyer - Mar 14, 2023 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Financial Officer
Signature
/s/ Russell Beyer
Stock symbol
SABS
Transactions as of
Mar 14, 2023
Transactions value $
$0
Form type
4
Date filed
3/16/2023, 04:27 PM
Previous filing
Sep 15, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Employee Stock Option (right to buy) Award $0 +275K $0.00 275K Mar 14, 2023 Common Stock 275K $0.54 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.